News – Page 925 – Endpoints News

Updated: Lonza sets sights on expansion, buying Novartis facility; IQVIA leads $14 million Series B funding round

6 years ago

Pfizer’s gamble on a new lease on life for aging sildenafil franchise fizzles in PhIII

6 years ago

In another shakeup, uBiome brings in outside help to revamp a microbiome testing operation under FBI scrutiny

6 years ago

Tesaro vet jumps to an Irish oncology upstart and shifts focus to the US, eyeing fundraising

6 years ago

Analysts see promise in FibroGen's early Duchenne study — now they want to see a pivotal trial

6 years ago

Semma steps toward the clinic after demonstrating effect of potential diabetes cure in landmark animal studies

6 years ago

Seducing Pfizer: How Array’s team patiently worked up the ladder to win an $11.4B bid from Albert Bourla

6 years ago

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval

6 years ago

Scoring Pfizer v Sarepta: This round on Duchenne gene therapy goes to the little biotech, but the pharma Goliath has ...

6 years ago

Unfazed by failure, PTC Therapeutics to appeal negative EMA decision on its disaster prone Duchenne drug

6 years ago

Evan Loh climbs the ladder to become CEO at Paratek Pharmaceuticals; Codiak's Doug Williams takes chairman's role at ...

6 years ago

Puretech-backed Karuna makes Nasdaq debut with $89M IPO

6 years ago

Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

6 years ago

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

6 years ago

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

6 years ago

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

6 years ago

OncoSec signs on Dana-Farber as CAR-T partner; Dova racks up another Doptelet approval

6 years ago

James Noble is taking his last lap at the biotech he founded, and saved. It's Adrian Rawcliffe's turn now

6 years ago

Targeting toxic protein aggregation, German biotech banks €12M to develop drug for rare neurodegenerative disorder

6 years ago

Beefing up its new gene therapy unit, Catalent inks $18M deal to snap up Novavax facilities

6 years ago

Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike

6 years ago

Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble

6 years ago

Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

6 years ago

BridgeBio takes crown for biggest biotech IPO of 2019, as fellow unicorn Adaptive raises offering size and price

6 years ago

First page Previous page 922 923 924925926 927 928 Next page Last page